CA2750727A1 - Treatment of inflammatory bowel diseases with mammal beta defensins - Google Patents

Treatment of inflammatory bowel diseases with mammal beta defensins Download PDF

Info

Publication number
CA2750727A1
CA2750727A1 CA2750727A CA2750727A CA2750727A1 CA 2750727 A1 CA2750727 A1 CA 2750727A1 CA 2750727 A CA2750727 A CA 2750727A CA 2750727 A CA2750727 A CA 2750727A CA 2750727 A1 CA2750727 A1 CA 2750727A1
Authority
CA
Canada
Prior art keywords
hbd2
beta defensin
human
tnf
lps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2750727A
Other languages
English (en)
French (fr)
Inventor
Tanja Maria Rosenkilde Kjaer
Thomas Kruse
Per Holse Mygand
Karoline Sidelmann Brinch
Soeren Kjaerulff
Birgitte Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Original Assignee
Novozymes Adenium Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2750727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech AS filed Critical Novozymes Adenium Biotech AS
Publication of CA2750727A1 publication Critical patent/CA2750727A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2750727A 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins Abandoned CA2750727A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP08160761.6 2008-07-18
EP08160761 2008-07-18
EP08162486.8 2008-08-15
EP08162486 2008-08-15
EP08163614 2008-09-03
EP08163614.4 2008-09-03
CA2730789A CA2730789A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2730789A Division CA2730789A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Publications (1)

Publication Number Publication Date
CA2750727A1 true CA2750727A1 (en) 2010-01-21

Family

ID=41530820

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2730789A Abandoned CA2730789A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins
CA2750727A Abandoned CA2750727A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2730789A Abandoned CA2730789A1 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Country Status (20)

Country Link
US (4) US8232242B2 (enExample)
EP (2) EP2320930A2 (enExample)
JP (2) JP2011528333A (enExample)
KR (1) KR20110092325A (enExample)
CN (2) CN102247591A (enExample)
AP (2) AP2011005755A0 (enExample)
AR (2) AR072032A1 (enExample)
AU (1) AU2009272681A1 (enExample)
BR (2) BRPI0915973A2 (enExample)
CA (2) CA2730789A1 (enExample)
CL (1) CL2011000099A1 (enExample)
EA (2) EA201170219A1 (enExample)
IL (2) IL210715A0 (enExample)
MX (1) MX2011000568A (enExample)
NZ (2) NZ593653A (enExample)
PH (1) PH12012501542A1 (enExample)
SG (1) SG172709A1 (enExample)
TW (2) TW201138810A (enExample)
WO (1) WO2010007166A2 (enExample)
ZA (1) ZA201100461B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590466A (en) * 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins
EP2320928B1 (en) * 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with human beta defensins
WO2010007166A2 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment of inflammatory bowel diseases with mammal beta defensins
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
EP3501284A1 (en) 2011-04-15 2019-06-26 Marine Polymer Technologies, Inc. Treatment of skin deseases with poly-n-acetyl glucosamine nanofibers
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
RU2740913C2 (ru) * 2016-04-29 2021-01-21 Дефенсин Терапьютикс Апс Лечение нарушений со стороны печени, желчных путей и поджелудочной железы
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화
MX2020005370A (es) 2017-11-24 2020-10-19 Defensin Therapeutics Aps Prevencion y tratamiento de enfermedad de injerto contra hospedero con defensinas.
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用
WO2024225153A1 (ja) * 2023-04-27 2024-10-31 サントリーホールディングス株式会社 免疫活性化用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
MXPA05006359A (es) * 2002-12-19 2006-02-08 Yitzchak Hillman Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
JP5491396B2 (ja) 2007-09-11 2014-05-14 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのデフェンシンペプチドの使用
WO2010007166A2 (en) 2008-07-18 2010-01-21 Novozymes A/S Treatment of inflammatory bowel diseases with mammal beta defensins
EP2320928B1 (en) * 2008-07-18 2012-11-07 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with human beta defensins
NZ590466A (en) 2008-07-18 2012-08-31 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide

Also Published As

Publication number Publication date
EP2320930A2 (en) 2011-05-18
WO2010007166A2 (en) 2010-01-21
US20120309678A1 (en) 2012-12-06
ZA201100461B (en) 2014-03-26
US20100016230A1 (en) 2010-01-21
EP2399600A1 (en) 2011-12-28
IL213680A0 (en) 2011-07-31
AR081948A2 (es) 2012-10-31
BRPI0924481A2 (pt) 2015-08-11
US8802621B2 (en) 2014-08-12
JP2011225596A (ja) 2011-11-10
NZ590468A (en) 2012-06-29
US20140135258A1 (en) 2014-05-15
JP2011528333A (ja) 2011-11-17
PH12012501542A1 (en) 2015-11-09
CN102247591A (zh) 2011-11-23
US8232242B2 (en) 2012-07-31
SG172709A1 (en) 2011-07-28
TW201004640A (en) 2010-02-01
IL210715A0 (en) 2011-03-31
US9279010B2 (en) 2016-03-08
CA2730789A1 (en) 2010-01-21
TW201138810A (en) 2011-11-16
AU2009272681A1 (en) 2010-01-21
AP2011005538A0 (en) 2011-02-28
WO2010007166A3 (en) 2010-06-03
BRPI0915973A2 (pt) 2013-05-07
EA201100910A1 (ru) 2012-05-30
MX2011000568A (es) 2011-02-23
US20110251139A1 (en) 2011-10-13
AR072032A1 (es) 2010-07-28
CN102159233A (zh) 2011-08-17
NZ593653A (en) 2012-09-28
EA201170219A1 (ru) 2011-08-30
AP2011005755A0 (en) 2011-06-30
CL2011000099A1 (es) 2011-10-07
KR20110092325A (ko) 2011-08-17

Similar Documents

Publication Publication Date Title
US8232242B2 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
EP2320929B1 (en) Human beta defensins for use in the treatment of inflammatory diseases
Zaiou et al. Cathelicidins, essential gene-encoded mammalian antibiotics
US9217021B2 (en) Oral treatment of inflammatory bowel disease
US8232248B2 (en) Treatment of rheumatoid arthritis with mammal beta defensins
AU2011203033A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
HK1164735A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
Class et al. Patent application title: Treatment Of Rheumatoid Arthritis With Mammal Beta Defensins Inventors: Tanja Maria Rosenkilde Kjaer (Holte, DK) Tanja Maria Rosenkilde Kjaer (Holte, DK) Thomas Kruse (Copenhagen N, DK) Per Holse Mygind (Vaerloese, DK) Per Holse Mygind (Vaerloese, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Karoline Sidelmann Brinch (Copenhagen Nv, DK) Soeren Kjaerulff (Holte, DK) Birgitte Andersen (Bagsvaerd, DK) Birgitte Andersen (Bagsvaerd, DK) Assignees: Novozymes A/S

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140717